Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
180
datasets available to search
ShareScore release 0.9.0
Dataset results
180 results for “fluconazole”
Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis
ClinicalTrials.gov study NCT00002040. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Comparison of Fluconazole and Amphotericin B in the Treatment of Cryptococcal Meningitis
ClinicalTrials.gov study NCT00002305. IPD Sharing: Not stated. Countries: 2. Publications: 0.
Comparative Randomized Study of the Efficacy, Safety, and Toleration of Fluconazole Oral Suspension or Nystatin Oral Suspension in the Treatment of Patients With Oropharyngeal Candidiasis in Associati
ClinicalTrials.gov study NCT00002112. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Effects of Single-dose and Steady-state TPV/RTV on the Steady-state Pharmacokinetics of Fluconazole in Healthy Adult Volunteers
ClinicalTrials.gov study NCT02195466. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Non-Comparative Study of Fluconazole in Patients With Serious Mycoses and Who Cannot Be Treated With Conventional Antifungal Therapy
ClinicalTrials.gov study NCT00002038. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Phase II Pilot Study of Fluconazole for Histoplasmosis, Blastomycosis, and Sporotrichosis
ClinicalTrials.gov study NCT00004808. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Safety and Pharmacokinetics of Oral F901318 (Fluconazole and Posaconazole) IN Aml Leukaemia
ClinicalTrials.gov study NCT03036046. IPD Sharing: NO. Countries: 0. Publications: 0.
A Study of Fluconazole in the Treatment of Cryptococcal Meningitis in Patients Who Have Not Had Success With Amphotericin B
ClinicalTrials.gov study NCT00002306. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Comparison of the Safety and Effectiveness of Fluconazole or Clotrimazole in the Treatment of Fungal Infections of the Mouth and Throat in Patients With AIDS
ClinicalTrials.gov study NCT00002282. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Comparison of SCH 56592 and Fluconazole in the Treatment of Oropharyngeal Candidiasis (OPC) in HIV-Positive Patients
ClinicalTrials.gov study NCT00002399. IPD Sharing: Not stated. Countries: 18. Publications: 0.
A Study of Fluconazole in the Treatment of Cryptococcal Meningitis in Patients With AIDS
ClinicalTrials.gov study NCT00002294. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Fractional CO₂ Laser or 40% Urea With Topical Fluconazole Microemulsion in Onychomycosis
ClinicalTrials.gov study NCT07033962. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Expression profilling of C. glabrata response to fluconazole in distinct growth conditions. Role of the Coregulator Pgd1 in such response.
GEO Series GSE174437. Nakaseomyces glabratus. 12 samples. Type: Expression profiling by high throughput sequencing.
Differential gene expression of Candida albicans under no stress conditions or fluconazole stress
GEO Series GSE184430. Candida albicans. 18 samples. Type: Expression profiling by high throughput sequencing.
Fluconazole reverses SHANK3-related autism-like deficits via lipid raft-driven IGF1R activation and prefrontal circuit remodeling
GEO Series GSE313444. Mus musculus. 2 samples. Type: Expression profiling by high throughput sequencing.
Dataset related to article "A reduced dose of fluconazole as primary antifungal prophylaxis is not associated with increased risk of invasive fungal infections after allogeneic stem cell transplantation from a HLA identical sibling"
<p>this record contains raw data related to article "A reduced dose of fluconazole as primary antifungal prophylaxis is not associated with increased risk of invasive fungal infections after allogeneic stem cell transplantation from a HLA identical sibling"</p> <p>BACKGROUND:</p> <p>Invasive fungal infections (IFI) represent a common side effect of allogeneic hematopoietic stem cell transplant (allo-SCT), resulting in increased non relapse mortality (NRM) and reduced overall survival (OS) rates. Seventy-five days of Fluconazole 400 mg/d represents the standard primary antifungal prophylaxis (PAP) after allo-SCT, especially for low-risk transplants. However, the ideal dosage of fluconazole has never been tested.</p> <p>METHODS:</p> <p>Here, we report the experience of our institution on 113 consecutive patients receiving an allo-SCT from a HLA identical sibling between 1999 and 2015, where PAP consisted of fluconazole 100 mg/d only during the pre-engraftment phase. At the time of transplant, all patients were considered at low-risk for mold infection according to ECIL-5 guidelines.</p> <p>RESULTS:</p> <p>Cumulative incidence of possible-probable-proven IFI was 11.7%, while proven-probable (PP-IFI) occurred in 5.5% of patients by day 100 post transplant. Of note, only 1 patient developed invasive Candidiasis due to a non-albicans strain and stool-screening tests were negative for colonization by Candida albicans species. The incidence of 1-year acute and 2-year chronic graft-versus-host-disease (GVHD) was 30% and 45%, respectively. Three-year OS and 1-year NRM were 53% and 11.3%, respectively.</p> <p>CONCLUSION:</p> <p>In summary, fungal prophylaxis with fluconazole 100 mg/d results in very low incidence of PP-IFI, GVHD and NRM in low-risk allo-SCT.</p>
Nevirapine Levels and Fluconazole
ClinicalTrials.gov study NCT00309582. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Genes Differentially Expressed as a result of a fluconazole-resistant variant Candida albicans strain CaLY188 with trisomy of Chromosome R.
GEO Series GSE48528. Candida albicans. 2 samples. Type: Expression profiling by array.
Effect of Candida albicans SC5314 under treatent of NT-a9, fluconazole or drug-free control.
GEO Series GSE297321. Candida albicans. 9 samples. Type: Expression profiling by high throughput sequencing.
Candida parapsilosis Mdr1B and Cdr1B are drivers of Mrr1-mediated clinical fluconazole resistance
GEO Series GSE196409. Candida parapsilosis. 18 samples. Type: Expression profiling by high throughput sequencing.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.